Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | PKM | P14618 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953841 | 1.00 | CYP2C19 (0.61) | CYP2C19ALDH1A1PKMGAAKMT2A | |
| SCHEMBL7623885 | 0.86 | CYP2C19 (0.73) | CYP2C19ALDH1A1PKMGAAKMT2A | |
| SCHEMBL3968323 | 0.83 | ALDH1A1 (0.56) | CYP2C19ALDH1A1PKMGAAKMT2A | |
| SCHEMBL29953713 | 0.83 | ALDH1A1 (0.56) | CYP2C19ALDH1A1PKMGAAKMT2A | |
| SCHEMBL9121912 | 0.83 | CYP2C19 (0.69) | CYP2C19ALDH1A1PKMGAAKMT2A | |
| SCHEMBL934547 | 0.82 | KMT2A (0.47) | CYP2C19ALDH1A1KMT2ABRD4MEN1 | |
| SCHEMBL5706236 | 0.82 | LMNA (0.52) | CYP2C19ALDH1A1PKMKMT2AMEN1 | |
| SCHEMBL18995906 | 0.81 | CYP2C19 (0.67) | CYP2C19ALDH1A1PKMGAAKMT2A | |
| SCHEMBL387555 | 0.81 | ALDH1A1 (0.60) | CYP2C19ALDH1A1PKMGAAKMT2A | |
| SCHEMBL28175168 | 0.79 | CYP2C19 (0.56) | CYP2C19ALDH1A1PKMGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340521-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2025-11-06 | — | — | US | disclosed |
| US-12435047-B2 | c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-10-07 | — | — | US | disclosed |
| CN-113840820-B | Phthalazinone compounds and uses thereof | ST制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| US-20230303501-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| US-11649218-B2 | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220235011-A1 | PHTHALAZINONE COMPOUNDS AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2022-07-28 | — | — | US | disclosed |
| EP-3978480-A1 | PHTHALAZINONE COMPOUNDS AND USE THEREOF | ST Pharm Co., Ltd. (KR) | 2022-04-06 | — | — | EP | disclosed |
| CN-113840820-A | Phthalazinone compounds and uses thereof | ST制药株式会社 | 2021-12-24 | — | — | CN | disclosed |
| US-20210101872-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2021-04-08 | — | — | US | disclosed |
| WO-2020242245-A1 | PHTHALAZINONE COMPOUNDS AND USE THEREOF | 에스티팜 주식회사 | 2020-12-03 | — | — | WO | disclosed |
| WO-2010100144-A1 | FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| EP-2114950-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009133127-A1 | FUSED BICYCLIC COMPOUNDS AND USE THEREOF AS PI3K INHIBITORS | MERCK SERONO S.A. (CH) | 2009-11-05 | — | — | WO | disclosed |
| EP-2046799-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Genentech, Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | US | disclosed |
| WO-2008073785-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| WO-2007127183-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435047-B2 | c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | ABL1, ABL2, MUSK | CYP2C19 4032/4885ALDH1A1 1314/4885PKM 2419/4885 |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | CYP2C19 6/4885ALDH1A1 530/4885PKM 1038/4885 |
| US-20230303501-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | ABL1, ABL2, MUSK | CYP2C19 4032/4885ALDH1A1 1314/4885PKM 2419/4885 |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIK3CA, PI4KB, PI4KA | CYP2C19 1813/4885ALDH1A1 2960/4885PKM 364/4885 |
| US-20220235011-A1 | PHTHALAZINONE COMPOUNDS AND USE THEREOF | SIRT6, SIRT1, SIRT2 | CYP2C19 1435/4885ALDH1A1 1433/4885PKM 335/4885 |
| US-11649218-B2 | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | ABL1, ABL2, MUSK | CYP2C19 4032/4885ALDH1A1 1314/4885PKM 2419/4885 |
| US-20250340521-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | ABL1, ABL2, MUSK | CYP2C19 4032/4885ALDH1A1 1314/4885PKM 2419/4885 |
| US-20210101872-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | ABL1, ABL2, MUSK | CYP2C19 4032/4885ALDH1A1 1314/4885PKM 2419/4885 |
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | CYP2C19 2680/4885ALDH1A1 4026/4885PKM 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.